The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Prescott Family Initiative at the Arizona Parkinson's Diseas, 2006The Prescott Family Initiative at The Arizona Parkinson's Disease Consortium
Parkinson's disease is currently diagnosed clinically by finding slowness of movement along with either rest tremor or rigidity. However, the only way to definitively diagnose PD is by autopsy. In...
-
Rapid Response Innovation Awards, 2010Biofeedback-based Motor Learning to Ameliorate Freezing of Gait
Objective/Rationale:
Our objective is to demonstrate that an intervention program based on motor learning principles can be applied to train subjects with Parkinson's disease (PD) who suffer from... -
Biomarkers, 2010Prospective Validation of Risk Markers for the Development of Parkinson’s Disease
Promising Outcomes of Original Grant:
As Parkinson’s disease is diagnosed when already a number of neurons have degenerated the PRIPS cohort consisting of 1847 healthy subjects older than 50 years was... -
Therapeutics Development Initiative, 2009Potential Efficacy of a Novel HDAC Inhibitor in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
Histone deacetylases (HDACs) are a family of enzymes that reduce gene expression and can regulate protein clearance. Inhibitors of HDACs have been reported to be efficacious in... -
Biomarkers, 2007Prospective Validation of Risk Markers for the Development of Parkinson’s Disease
Objective/Rationale:
The development of disease-course modifying or neuroprotective treatments is still an unmet therapeutical need in Parkinson’s disease. Treatment will likely work best if initiated... -
Research Grant, 2017Validation of the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) for Parkinson's Disease
Study Rationale:
The US Food and Drug (FDA) requires acceptable outcome measures to approve a cognitive-enhancing medication for the treatment of mild cognitive impairment (MCI) in Parkinson's disease...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.